Theravance Biopharma, Inc. (TBPH) Cash flow
Market cap
$849.63M
P/E ratio
8x
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 3 | 3 | 3 | 4 | 3 | - | - | - | - | - | - | - |
| Stock-based compensation | 43 | 54 | 41 | 49 | 51 | 60 | 63 | 62 | 40 | 25 | 21 | 18 |
| Cash from operations | -175 | -169 | -99 | -201 | -113 | -238 | -250 | -208 | -2 | -27 | -12 | 239 |
| Capital expenditures | -3 | -3 | -2 | -2 | -7 | -3 | -7 | -3 | -1 | -2 | -0 | -0 |
| Cash from investing | -106 | 111 | -148 | -56 | 177 | -83 | 11 | 124 | 1,154 | -33 | 12 | -105 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 129 | 197 | 0 | - |
| Proceeds from issuance of term debt, net | - | - | - | - | - | - | 380 | - | - | - | - | - |
| Cash from financing | 371 | 81 | 479 | 2 | 225 | 1 | 263 | 92 | -739 | -199 | -2 | -3 |
| Free cash flow | ||||||||||||
| FCF margin (%) |